Research Overview

research-overview.jpg

Our laboratory investigates how chromatin regulators and their condensate assemblies control gene expression and cell fate. We seek to understand how these mechanisms operate in normal development and how their dysregulation drives cancer, with the goal of identifying new therapeutic opportunities.

Our research integrates biochemistry, genetics, advanced imaging, genomics and epigenomics, and computational approaches. By combining mechanistic studies with disease models, we investigate how altered chromatin regulation and nuclear organization establish pathogenic gene programs, disrupt differentiation, and promote cellular plasticity.


Decoding the Epigenome

Research-decoding the epigenome.jpg

Our genome is decorated with diverse chemical modifications on the histone proteins that package DNA. These modifications constitute an essential layer of information, referred to as the epigenome, that regulates genome architecture and function. How this information is interpreted to affect a cell’s fate and behavior, and how this process goes awry in human disease, remain poorly understood. Ongoing projects focus on chromatin readers—proteins that recognize specific histone modifications. We seek to understand how reader-mediated processes translate epigenetic information into downstream events that determine cell fate, and how cancer-associated mutations disrupt these processes.


Dysregulation of nuclear Condensates in Cancer

Proper gene expression requires the assembly and coordination of many proteins, but the mechanisms underlying this process remain incompletely understood. Studies have shown that some gene regulators form dynamic, high-concentration assemblies known as condensates. Increasing evidence, including our own research, indicates that cancer-associated mutations in gene regulators drive oncogenic programs by creating aberrant condensates. We investigate how these condensates form and are regulated by interactions among proteins, chromatin, and RNA; their effects on gene regulation and 3D genome architecture; and their pathogenic roles in disease models.


Epigenomic Reprograming and Cell Plasticity

Cancer cells are difficult to eliminate because they are highly adaptive and resilient. Epigenomic reprogramming is emerging as an important mechanism underlying changes in cell identity and behavior. This is particularly relevant during cancer metastasis, when cells must continually adapt to changing microenvironments. We investigate how altered chromatin states enable cancer cells to acquire the plasticity needed to adapt and thrive during tumor progression, metastasis, and therapeutic resistance.


Drugging the Epigenome

Drugging the Epigenome.jpg

Epigenetic dysregulation is a common feature of many cancers. The field of cancer epigenetics has witnessed exciting translation of basic mechanistic understanding to the development of epigenetic modulatory drugs as novel cancer therapies. However, for many agents, their mechanisms of action—including what determines therapeutic response and resistance—remain poorly understood. We are actively engaged in the development and characterization of approaches that target chromatin regulators and pathogenic condensates.